57
Views
2
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Overexpression of phosphorylated p27Kip1 at threonine 187 may predict outcome in aggressive B-cell lymphomas

, , , &
Pages 814-822 | Received 13 Dec 2010, Accepted 11 Jan 2011, Published online: 21 Feb 2011
 

Abstract

Phosphorylation of p27Kip1 at threonine 187 (pThr187-p27Kip1) occurs frequently in the development of human tumors, directing protein polyubiquitination and subsequent proteasomal degradation. We investigated the immunoexpression of p27Kip1 and pThr187-p27Kip1 in 126 B-cell lymphomas and their relation to proliferative activity and clinical parameters. Increased levels of p27Kip1 and pThr187-p27Kip1 were significantly correlated with indolent and aggressive lymphomas, respectively (p < 0.001). pThr187-p27Kip1 expression showed a strong positive correlation with proliferation index in aggressive (p = 0.01) and indolent (p < 0.001) subgroups. Survival analysis revealed that pThr187-p27Kip1 was an unfavorable prognostic factor for disease-free (p = 0.019) and overall survival (p = 0.003) in aggressive lymphomas. Cox regression analysis demonstrated that the prognostic value of pThr187-p27Kip1 was independent of the international prognostic index (IPI) score, tumor stage, patient age, and serum lactate dehydrogenase (LDH) level. Overall, our results suggest that high levels of pThr187-p27Kip1 may predict a worse clinical outcome in patients with aggressive lymphomas.

Potential conflict of interest: Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.